Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Publication
, Journal Article
Bitting, RL; Armstrong, AJ; George, DJ
Published in: Clin Med Insights Oncol
2011
Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.
Duke Scholars
Published In
Clin Med Insights Oncol
DOI
EISSN
1179-5549
Publication Date
2011
Volume
5
Start / End Page
325 / 332
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Bitting, R. L., Armstrong, A. J., & George, D. J. (2011). Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clin Med Insights Oncol, 5, 325–332. https://doi.org/10.4137/CMO.S5977
Bitting, Rhonda L., Andrew J. Armstrong, and Daniel J. George. “Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?” Clin Med Insights Oncol 5 (2011): 325–32. https://doi.org/10.4137/CMO.S5977.
Bitting RL, Armstrong AJ, George DJ. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clin Med Insights Oncol. 2011;5:325–32.
Bitting, Rhonda L., et al. “Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?” Clin Med Insights Oncol, vol. 5, 2011, pp. 325–32. Pubmed, doi:10.4137/CMO.S5977.
Bitting RL, Armstrong AJ, George DJ. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clin Med Insights Oncol. 2011;5:325–332.
Published In
Clin Med Insights Oncol
DOI
EISSN
1179-5549
Publication Date
2011
Volume
5
Start / End Page
325 / 332
Location
United States